NEW YORK – Natera said on Monday that the US District Court for the District of Delaware denied CareDx's motion for summary judgement on two patents held by Natera that form part of a lawsuit that Natera filed against CareDx.
The court also ruled that the two patents asserted by Natera, which cover the company's Panorama noninvasive prenatal testing assay technology, will proceed to a trial scheduled to begin on Jan. 22 of next year.
Natera and CareDx have filed various lawsuits against each other for some time.
In March of last year, a jury awarded CareDx $44.9 million in damages related to false advertising in another lawsuit brought against Natera. A ruling later, however, voided those damages, ruling that CareDx failed to link any false statement to customer reliance on said advertising.
"We are gratified that the court has issued a decision that provides a clear path to trial as we work to protect our significant investments in innovation from unlawful infringement," Natera said in a statement.